Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa

Inclusion Criteria:

• Age above 18 and under 80 years of age, both gender, in good health.

• Clinical diagnosis of retinitis pigmentosa, the results of eye electrophysiologicalexamination accord with retinitis pigmentosa.

• The BCVA of target eye will not be better than 20/400.

• The BCVA of contralateral eye is not worse than 20/400.

• Diopter is smaller than 8.00 D, axial 28 mm or less.

• Voluntary as test subjects, signed informed consent, regular follow-up will beeffected according to the specified time.

Exclusion Criteria:

• Subject with other additional retinal diseases, like diabetic or hypertensiveretinopathy vascular diseases.

• Target eye ever have had a eye surgery;

• Subject with active serious diseases of the digestive system, liver kidney impairment (ALT/AST) > 1.5 or any known liver disease, creatine > 1.3 mg/dL) and/serious temicdiseases, such as cardiovascular tem, respiratory tem, nervous tem, endocrine temurogenital tem diseases, etc.), the history of malignancy;

• Have been ready for pregnancy during test, are lactating women;

• Ready to birth of men during the test;

• Subject with any immunodeficiency;

• Subject in the immunosuppressive therapy in the current;

• Subject with the tacrolimus or other large ring lactone class drug allergies;

• Participate in any clinical subjects in nearly six months;

• Has a history of alcohol or illicit drug abuse;

• Poor adherence to complete studies;

• Researchers believe that there may be an increased risk subjects or interfere with theclinical trials of any situation (such as when a patient is prone to mental tension,depression, mental illness, cognitive dysfunction, etc.).